Lost Ground: Cancer Screening in the COVID-19 Era
A pandemic-related drop in cancer diagnoses could spell long-term trouble for patients and providers.
A pandemic-related drop in cancer diagnoses could spell long-term trouble for patients and providers.
From - Diagnostic Testing & Emerging Technologies
Venture capital investments in health care innovation reached an all time high in 2017, including in diagnostics/tools (Dx/Tools) companies, according to…
From - Diagnostic Testing & Emerging Technologies
In a continued reversal of its 2013 crackdown on direct-to-consumer (DTC) genetic tests, the U.S. Food and Drug Administration (FDA) unveiled…
From - Diagnostic Testing & Emerging Technologies
A 36-year-old Oregon woman filed a $1.8 million medical malpractice lawsuit against her doctors and a southwest Oregon medical center for…
By Kyle Fetter bio
The final 2018 clinical laboratory fee schedule (CLFS) is out, and it is evident that the argument that the Centers for Medicare & Medicaid Services (CMS) PAMA process was…
By Mike O'Brien bio
Your news feed, like mine, has exploded with references to someone named Harvey Weinstein for the past few weeks. What's up? Weinstein is…
From - Diagnostic Testing & Emerging Technologies
In the kick-off event of G2 Intelligence's 2017 Laboratory Institute (Washington D.C.; Oct. 25-27), representatives of the biggest laboratory-related associations shared…